Which has preferable earnings & valuation, NBTX or QGEN?

Qiagen has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 46.32 -$27.11M N/A N/A Qiagen $2.09B 3.59 $424.88M $1.91 19.08

Is NBTX or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Nanobiotix's net margin of 0.00%. Qiagen's return on equity of 14.40% beat Nanobiotix's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Qiagen 19.16% 14.40% 8.40%

Does the media refer more to NBTX or QGEN?

In the previous week, Qiagen had 15 more articles in the media than Nanobiotix. MarketBeat recorded 18 mentions for Qiagen and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.22 beat Qiagen's score of -0.43 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, NBTX or PCVX?

Nanobiotix has higher revenue and earnings than Vaxcyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 46.32 -$27.11M N/A N/A Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is NBTX or PCVX more profitable?

Nanobiotix's return on equity of 0.00% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Vaxcyte N/A -32.51% -29.51%

Does the media refer more to NBTX or PCVX?

In the previous week, Vaxcyte had 4 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Vaxcyte and 3 mentions for Nanobiotix. Vaxcyte's average media sentiment score of 0.31 beat Nanobiotix's score of 0.22 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, IMVT or NBTX?

Nanobiotix has higher revenue and earnings than Immunovant. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A Nanobiotix $36.87M 46.32 -$27.11M N/A N/A

Is IMVT or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Nanobiotix N/A N/A N/A

Does the media prefer IMVT or NBTX?

In the previous week, Immunovant had 5 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Immunovant and 3 mentions for Nanobiotix. Immunovant's average media sentiment score of 0.35 beat Nanobiotix's score of 0.22 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, LNTH or NBTX?

Lantheus has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.23 $233.56M $4.15 24.16 Nanobiotix $36.87M 46.32 -$27.11M N/A N/A

Is LNTH or NBTX more profitable?

Lantheus has a net margin of 18.05% compared to Nanobiotix's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Nanobiotix's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Nanobiotix N/A N/A N/A

Does the media prefer LNTH or NBTX?

In the previous week, Lantheus had 2 more articles in the media than Nanobiotix. MarketBeat recorded 5 mentions for Lantheus and 3 mentions for Nanobiotix. Lantheus' average media sentiment score of 0.44 beat Nanobiotix's score of 0.22 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, KYMR or NBTX?

Nanobiotix has lower revenue, but higher earnings than Kymera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 153.52 -$311.35M -$3.57 N/A Nanobiotix $36.87M 46.32 -$27.11M N/A N/A

Does the media favor KYMR or NBTX?

In the previous week, Kymera Therapeutics had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for Kymera Therapeutics and 3 mentions for Nanobiotix. Kymera Therapeutics' average media sentiment score of 0.64 beat Nanobiotix's score of 0.22 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nanobiotix (NBTX) Competitors

$35.20 -1.56 (-4.24%)

Closing price 04:00 PM Eastern

Extended Trading

$35.21 +0.01 (+0.03%)

As of 07:48 PM Eastern

Compare

NBTX vs. QGEN, PCVX, IMVT, LNTH, and KYMR

Should you buy Nanobiotix stock or one of its competitors? MarketBeat compares Nanobiotix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nanobiotix include Qiagen (QGEN), Vaxcyte (PCVX), Immunovant (IMVT), Lantheus (LNTH), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Nanobiotix compare to Qiagen?

Nanobiotix (NASDAQ:NBTX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Qiagen has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	46.32	-$27.11M	N/A	N/A
Qiagen	$2.09B	3.59	$424.88M	$1.91	19.08

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Qiagen has a net margin of 19.16% compared to Nanobiotix's net margin of 0.00%. Qiagen's return on equity of 14.40% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Qiagen	19.16%	14.40%	8.40%

Nanobiotix has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

In the previous week, Qiagen had 15 more articles in the media than Nanobiotix. MarketBeat recorded 18 mentions for Qiagen and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.22 beat Qiagen's score of -0.43 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix currently has a consensus target price of $26.67, suggesting a potential downside of 24.24%. Qiagen has a consensus target price of $44.98, suggesting a potential upside of 23.41%. Given Qiagen's higher probable upside, analysts clearly believe Qiagen is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Summary

Qiagen beats Nanobiotix on 10 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Vaxcyte?

Nanobiotix (NASDAQ:NBTX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Nanobiotix has higher revenue and earnings than Vaxcyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	46.32	-$27.11M	N/A	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nanobiotix has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

In the previous week, Vaxcyte had 4 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Vaxcyte and 3 mentions for Nanobiotix. Vaxcyte's average media sentiment score of 0.31 beat Nanobiotix's score of 0.22 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix's return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Vaxcyte	N/A	-32.51%	-29.51%

Nanobiotix currently has a consensus target price of $26.67, suggesting a potential downside of 24.24%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 83.25%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Vaxcyte beats Nanobiotix on 7 of the 12 factors compared between the two stocks.

How does Nanobiotix compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immunovant presently has a consensus price target of $37.33, suggesting a potential upside of 19.85%. Nanobiotix has a consensus price target of $26.67, suggesting a potential downside of 24.24%. Given Immunovant's higher possible upside, research analysts clearly believe Immunovant is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has higher revenue and earnings than Immunovant.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Nanobiotix	$36.87M	46.32	-$27.11M	N/A	N/A

In the previous week, Immunovant had 5 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Immunovant and 3 mentions for Nanobiotix. Immunovant's average media sentiment score of 0.35 beat Nanobiotix's score of 0.22 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Nanobiotix	N/A	N/A	N/A

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

Immunovant and Nanobiotix tied by winning 6 of the 12 factors compared between the two stocks.

How does Nanobiotix compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Lantheus presently has a consensus price target of $101.86, suggesting a potential upside of 1.60%. Nanobiotix has a consensus price target of $26.67, suggesting a potential downside of 24.24%. Given Lantheus' stronger consensus rating and higher probable upside, equities analysts plainly believe Lantheus is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Lantheus has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.16
Nanobiotix	$36.87M	46.32	-$27.11M	N/A	N/A

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Lantheus had 2 more articles in the media than Nanobiotix. MarketBeat recorded 5 mentions for Lantheus and 3 mentions for Nanobiotix. Lantheus' average media sentiment score of 0.44 beat Nanobiotix's score of 0.22 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Nanobiotix's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Nanobiotix	N/A	N/A	N/A

Summary

Lantheus beats Nanobiotix on 11 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Kymera Therapeutics presently has a consensus target price of $118.10, indicating a potential upside of 61.38%. Nanobiotix has a consensus target price of $26.67, indicating a potential downside of 24.24%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kymera Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Kymera Therapeutics had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for Kymera Therapeutics and 3 mentions for Nanobiotix. Kymera Therapeutics' average media sentiment score of 0.64 beat Nanobiotix's score of 0.22 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Nanobiotix has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Nanobiotix's return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Nanobiotix	N/A	N/A	N/A

Nanobiotix has lower revenue, but higher earnings than Kymera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	153.52	-$311.35M	-$3.57	N/A
Nanobiotix	$36.87M	46.32	-$27.11M	N/A	N/A

38.8% of Nanobiotix shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Kymera Therapeutics beats Nanobiotix on 10 of the 15 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.71B	$2.91B	$6.45B	$12.42B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	N/A	17.69	22.30	24.19
Price / Sales	46.32	739.65	581.44	138.36
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	-17.87	3.85	9.84	6.72
Net Income	-$27.11M	$75.85M	$3.57B	$337.19M
7 Day Performance	-13.09%	-1.67%	-1.16%	0.48%
1 Month Performance	0.23%	22.18%	3.85%	5.07%
1 Year Performance	749.22%	21.83%	27.40%	34.25%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	2.0355 of 5 stars	$35.20 -4.2%	$26.67 -24.2%	+789.2%	$1.78B	$36.87M	N/A	100	Short Interest Increase Gap Down
QGEN Qiagen	4.1509 of 5 stars	$35.34 +0.5%	$44.98 +27.3%	-24.4%	$7.28B	$2.09B	18.46	5,654
PCVX Vaxcyte	2.7419 of 5 stars	$49.75 +5.2%	$86.00 +72.9%	+35.4%	$7.18B	N/A	N/A	160	Insider Trade
IMVT Immunovant	2.3558 of 5 stars	$33.96 -0.6%	$37.33 +9.9%	+100.6%	$6.97B	N/A	N/A	120	Gap Up
LNTH Lantheus	2.1119 of 5 stars	$100.67 -2.3%	$99.71 -0.9%	+24.9%	$6.55B	$1.54B	24.26	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors